Literature DB >> 2456210

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.

D A Einfeld1, J P Brown, M A Valentine, E A Clark, J A Ledbetter.   

Abstract

CD20 is an antigen expressed on normal and malignant human B cells that is thought to function as a receptor during B cell activation. Here we report the isolation of a CD20-specific cDNA clone from a lambda gt11 library using a polyclonal antiserum raised against purified CD20 antigen. Additional cDNA clones were then isolated from a lambda gt10 library. Alignment of the sequences of overlapping lambda clones reveal a single consensus sequence except for a divergence that preceded the first methionine within the open reading frame. Normal B cells and B cell lines contain a prominent 2.6 kb mRNA and a lower level of a 3.3 kb mRNA. An oligonucleotide derived from one of the divergent sequences hybridized to the 3.3 kb mRNA only, indicating that the two mRNA species are derived from an alternative splicing mechanism. The predicted amino acid sequence of CD20 reveals three major hydrophobic regions of approximately 53, 25 and 20 amino acids. CD20 lacks an NH2-terminal signal peptide and contains a highly charged COOH-terminal domain. Although CD20 is immunoprecipitated as a doublet of 33 and 35 kd proteins from B cells, in vitro translation of CD20 cDNA produced a single 33 kd protein that was specifically immunoprecipitated with monoclonal CD20 antibodies. CD20 was strongly phosphorylated on resting B cells after CDw40 stimulation, suggesting that CD20 may be functionally regulated by a protein kinase(s).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456210      PMCID: PMC454379          DOI: 10.1002/j.1460-2075.1988.tb02867.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  39 in total

1.  Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells.

Authors:  E B Smeland; K Beiske; R Ohlsson; H Holte; E Ruud; H K Blomhoff; R Jefferis; T Godal
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

2.  Efficient isolation of genes by using antibody probes.

Authors:  R A Young; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

3.  Structure of the lac carrier protein of Escherichia coli.

Authors:  D L Foster; M Boublik; H R Kaback
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

4.  Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing.

Authors:  F Sanger; A R Coulson; B G Barrell; A J Smith; B A Roe
Journal:  J Mol Biol       Date:  1980-10-25       Impact factor: 5.469

5.  pEMBL: a new family of single stranded plasmids.

Authors:  L Dente; G Cesareni; R Cortese
Journal:  Nucleic Acids Res       Date:  1983-03-25       Impact factor: 16.971

6.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

7.  Complete mRNA coding sequence of the acetylcholine binding alpha-subunit of Torpedo marmorata acetylcholine receptor: a model for the transmembrane organization of the polypeptide chain.

Authors:  A Devillers-Thiery; J Giraudat; M Bentaboulet; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

8.  Molecular cloning of cDNA coding for the gamma subunit of Torpedo acetylcholine receptor.

Authors:  M Ballivet; J Patrick; J Lee; S Heinemann
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Structural homology of Torpedo californica acetylcholine receptor subunits.

Authors:  M Noda; H Takahashi; T Tanabe; M Toyosato; S Kikyotani; Y Furutani; T Hirose; H Takashima; S Inayama; T Miyata; S Numa
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

View more
  39 in total

Review 1.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

2.  Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.

Authors:  Alberto Lerario; Filippo Cogiamanian; Chiara Marchesi; Marzia Belicchi; Nereo Bresolin; Laura Porretti; Yvan Torrente
Journal:  BMC Musculoskelet Disord       Date:  2010-07-11       Impact factor: 2.362

3.  Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.

Authors:  Russell N Johnson; Pavla Kopečková; Jindřich Kopeček
Journal:  Biomacromolecules       Date:  2012-02-21       Impact factor: 6.988

Review 4.  How does B cell depletion therapy work, and how can it be improved?

Authors:  E A Clark; J A Ledbetter
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 5.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 6.  One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.

Authors:  Hyunbo Shim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

7.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Authors:  Eugenia Zah; Meng-Yin Lin; Anne Silva-Benedict; Michael C Jensen; Yvonne Y Chen
Journal:  Cancer Immunol Res       Date:  2016-04-08       Impact factor: 11.151

9.  CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Authors:  Nathalie A Johnson; Stephen Leach; Bruce Woolcock; Ronald J deLeeuw; Ali Bashashati; Laurie H Sehn; Joseph M Connors; Mukesh Chhanabhai; Angela Brooks-Wilson; Randy D Gascoyne
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

10.  Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Authors:  Claudio Galarza; Diana Valencia; Gabriel J Tobón; Luis Zurita; Rubén D Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan C Rueda; Juan-Manuel Anaya
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.